Standout Papers
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies (2011)
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance (2006)
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016)
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013)
Immediate Impact
4 by Nobel laureates 16 from Science/Nature 73 standout
Citing Papers
Succinate Nanomaterials Boost Tumor Immunotherapy via Activating Cell Pyroptosis and Enhancing MHC-I Expression
2025 Standout
Mechanisms driving the immunoregulatory function of cancer cells
2023 Standout
Works of Brian D. Lehmann being referenced
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
2021
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Brian D. Lehmann | 5581 | 5602 | 4317 | 70 | 10.9k | |
| Jocelyne Jacquemier | 6118 | 4595 | 4369 | 108 | 10.6k | |
| Andrea L. Richardson | 6291 | 7044 | 3716 | 63 | 11.7k | |
| Emmanuelle Charafe‐Jauffret | 7632 | 7044 | 4658 | 138 | 12.6k | |
| Melinda E. Sanders | 6377 | 5909 | 4657 | 111 | 12.9k | |
| Pascal Finetti | 4850 | 4592 | 3435 | 175 | 9.6k | |
| Philip S. Bernard | 5090 | 4873 | 5534 | 91 | 10.9k | |
| Christophe Ginestier | 8027 | 7036 | 4259 | 94 | 12.6k | |
| Luc Girard | 4382 | 8008 | 2944 | 164 | 12.0k | |
| Laura J. van’t Veer | 5289 | 5139 | 4529 | 123 | 11.5k | |
| Edward Gabrielson | 3390 | 9802 | 3036 | 133 | 13.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...